Association of Lipid Profile With Cardiovascular Diseases and All‐Cause Death: A 2‐Decade Follow‐Up of the Tehran Lipid and Glucose Study
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.040554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Azra Ramezankhani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Prevention of Metabolic Disorders Research Center Research Institute for Metabolic and Obesity Disorders, Research Institute for Endocrine Sciences, …. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Lipids, Dyslipidemias. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
We investigated the associations between total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol (HDL‐C), non–HDL‐C, and triglycerides with all‐cause and cardiovascular disease death among participants in the TLGS (Tehran Lipid and Glucose Study) cohort.
Methods
We included 8241 participants aged ≥30 years, who were followed until 2018. Lipid profiles were assessed as both continuous and categorical variables (quintiles) using the restricted cubic spline and Cox proportional hazards model.
Results
During a median follow‐up of 18.1 years, 1002 and 369 individuals died from all causes and cardiovascular disease, respectively. A U‐shaped association was found between non–HDL‐C and the risk of all‐cause death. In the categorical analyses for all‐cause death, individuals in quintile 1 of non–HDL‐C had a hazard ratio (HR) of 1.35 (95% CI, 1.09–1.68), compared with quintile 2 (reference). Additionally, those in quintiles 1 and 3 of total cholesterol had HRs of 1.34 (95% CI, 1.08–1.67) and 1.25 (95% CI, 1.02–1.55), respectively, relative to quintile 2 (reference). Regarding cardiovascular disease death, linear associations were observed for total cholesterol, low‐density lipoprotein cholesterol, and non–HDL‐C. In categorical analysis, quintiles 3 and 5 of total cholesterol had HRs of 1.87 (95% CI, 1.30–2.70) and 1.78 (95% CI, 1.25–2.53), respectively, compared with quintile 2 (reference). Furthermore, compared with quintile 1 of low‐density lipoprotein cholesterol (reference), individuals in quintiles 3 and 5 had HRs of 1.62 (95% CI, 1.08–2.42) and 1.81 (95% CI, 1.24–2.66), respectively. For non–HDL‐C, the HR for quintile 5 was 1.43 (95% CI, 1.00–2.06) compared with quintile 1 (reference).
Conclusions
In the general population, low and high levels of non–HDL‐C were associated with an increased risk of all‐cause death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prevention of Metabolic Disorders Research Center Research Institute for Metabolic and Obesity Disorders, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences Tehran Iran.
- Endocrine Research Center Research Institute for Endocrine Disorders, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences Tehran Iran.
ORCID-Profile: Azra Ramezankhani, Fereidoun Azizi, Farzad Hadaegh
Zitieren
APA
Ramezankhani, A., Azizi, F., & Hadaegh, F. (2025). Association of Lipid Profile With Cardiovascular Diseases and All‐Cause Death: A 2‐Decade Follow‐Up of the Tehran Lipid and Glucose Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040554
Vancouver
Ramezankhani A, Azizi F, Hadaegh F. Association of Lipid Profile With Cardiovascular Diseases and All‐Cause Death: A 2‐Decade Follow‐Up of the Tehran Lipid and Glucose Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040554
BibTeX
@article{Ramezankhani2025,
author = {Ramezankhani, Azra and Azizi, Fereidoun and Hadaegh, Farzad},
title = {Association of Lipid Profile With Cardiovascular Diseases and All‐Cause Death: A 2‐Decade Follow‐Up of the Tehran Lipid and Glucose Study},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.040554}
}
EUVIMED